imageimageMetastatic primary tumours upregulate Upp1 in neutrophils, which elevates circulating uracil. UPP1-expressing neutrophils accumulate in the lung where they inhibit CD8+ T cells, promote fibr...

The dynamics of microglia states adjacent to or far from amyloid-beta plaques are unclear. Here the authors show that non-plaque-associated microglia modulate the cell population expansion in response...

Please refer to the How to Apply for a Job (for External Candidates) job aid for instructions on how to apply. If you are an active McGill employee (ie: currently in an active contract or position at ...

Systemic responses during tumor progression reshape granulopoiesis. In this issue of Cancer Cell, Garner et al. show that tumor-derived signals reprogram neutrophil development early in myelopoiesis. ...

Sensory innervation impacts several lung diseases, but whether it influences pulmonary fibrosis (PF) is unclear. Hiroki et al. report that depletion of TRPV1+ nociceptors leads to worsening of inflamm...

Une nouvelle étude menée par Hannah Garner, Ph.D., nouvellement chercheuse à l’Institut du cancer Rosalind et Morris Goodman (ICG), publiée dans le journal Cancer Cell, a montré que les cellules...

A recent study from Hannah Garner, Ph.D. and new member of the Rosalind and Morris Goodman Cancer Institute (GCI), published in Cancer Cell, showed that neutrophil precursors located in the bone marrow receive signals from mammary tumours and promote metastasis.

Tumor-induced systemic accumulation and polarization of neutrophils to an immunosuppressive phenotype is a potent driver of metastasis formation. Yet,…

Vaccines generate long-lived plasma cells and memory B cells (Bmems) that may re-enter secondary germinal centers (GCs) to further mutate their B cell…

Clonal hematopoiesis is the expansion of a genetically related population of hematopoietic stem and progenitor cells that disproportionately contribute to blood-cell production.1 Clonal hematopoies...

The Marathon of Hope Cancer Centres Network (MOHCCN), led by the Terry Fox Research Institute and the Terry Fox Foundation, unites researchers, clinicians, patients, funders, and other partners across Canada to accelerate precision oncology, promote collaboration and data sharing, and ultimately improve patient outcomes. This overview outlines the Network’s goals, history, and challenges and opportunities. We also highlight progress toward the “MOHCCN Gold Cohort,” a shared resource of clinical and genomic data from 15,000 patients.